Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I0TD
|
|||
| Former ID |
DIB008777
|
|||
| Drug Name |
AZM-134
|
|||
| Synonyms |
AZM-133; GLP-1 mimetics, Alizyme; Glucagon-like peptide-1 mimetics, Alizyme
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Terminated | [1] | |
| Company |
Alizyme plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Modulator | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008696) | |||
| REF 2 | US patent application no. 2011,0171,312, Modified therapeutic peptides, methods of their preparation and use. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.